Analyst Price Targets — AKBA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 7, 2026 10:16 am | — | Leerink Partners | $1.00 | $0.95 | TheFly | Akebia downgraded to Market Perform from Outperform at Leerink |
| February 6, 2026 11:51 am | Allison Bratzel | Piper Sandler | $4.00 | $1.38 | TheFly | Akebia price target lowered to $4 from $6 at Piper Sandler |
| March 28, 2024 12:08 pm | Ed Arce | H.C. Wainwright | $6.00 | $1.98 | TheFly | Akebia price target raised to $6 from $5 at H.C. Wainwright |
| March 3, 2022 12:00 am | Serge Belanger | Needham | $7.00 | $2.65 | Pulse 2.0 | Akebia Therapeutics (AKBA) Stock: $7 Price Target And Buy Rating |
Latest News for AKBA
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 8,400 shares of Akebia's common stock on August 31, 2026.
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P.
Akebia Therapeutics, Inc. (AKBA) Q2 2026 Earnings Call Transcript
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to break-even earnings per share a year ago.
Akebia Therapeutics NASDAQ: AKBA reported second-quarter revenue growth for its Vafseo anemia treatment while highlighting an interim clinical result from the VOICE study and progress across its kidney disease pipeline.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AKBA.
U.S. House Trading
No House trades found for AKBA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.